Aptose Biosciences Inc (APS.TO) remains stable this week as it completes its acquisition by Hanmi Pharmaceutical.
Aptose Biosciences Inc has reported no significant changes in its stock price this week, maintaining its last close at C$2.40. The company recently completed its acquisition by Hanmi Pharmaceutical, marking a pivotal moment in its corporate trajectory. This update explores the stock's technical picture and recent performance metrics.
Investor takeaway: With Aptose's stock showing stability amid its acquisition completion, investors may want to consider the company's strategic direction post-acquisition and its ongoing clinical developments.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Aptose Biosciences Inc
APS.TO
APS.TO
Aptose Biosciences Inc
WealthAwesomeMarket cap
$6.13M
52W high
$2.59
52W low
$1.41
1W change
+0.00%
Beta
0.34
Analyst Price Targets
Based on analyst covering APS
Wall Street analysts forecast APS stock price to fall 1.7% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.36
-1.7% Upside
Current Price
C$2.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APS's historical volatility
30-Day Vol
52.7%
Annualized
90-Day Vol
48.9%
Annualized
Trend (90d)
-0.0%
Annualized drift
90d Mean
C$2.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.40 | C$2.00 – C$2.88 |
| 60 trading days | C$2.40 | C$1.86 – C$3.10 |
| 90 trading days | C$2.40 | C$1.75 – C$3.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
C$2.40 Closing Price with 12.15% Monthly Gain
Aptose's stock has increased by 12.15% over the past month, reflecting some positive momentum despite the lack of major news this week.
Bull case
The acquisition by Hanmi Pharmaceutical could give Aptose more capital and resources. This may help speed up its clinical trials and broaden its market reach.
Bear case
Even with the acquisition, Aptose's financial performance raises concerns, as shown by its negative return on equity and profit margin. Investors should be cautious about the company's long-term prospects.
Recent Price Action
Aptose Biosciences Inc (APS.TO) has maintained a stable price point, closing at C$2.40 this week. The stock has not experienced any significant fluctuations, remaining unchanged over the past day. However, it has gained 12.15% over the last month, indicating some positive momentum in a generally challenging market environment.
Company News and Headlines
Advertisement
This week, Aptose Biosciences completed its acquisition by Hanmi Pharmaceutical, marking a significant transition for the company. This acquisition is seen as a strategic move that may enhance Aptose's capabilities in drug development and market penetration. Additionally, Aptose presented clinical data at the 2026 EHA Congress, showcasing its progress in the TUSCANY Phase 1/2 clinical trial for acute myeloid leukemia.
Technical Picture
The technical indicators for Aptose show a 50-day moving average of C$2.25, which is 6.4% above the current price, and a 200-day moving average of C$2.14, indicating a 12.3% increase. The stock's 52-week range is between C$1.41 and C$2.59, with the current price at approximately 84% of this range. The beta of 0.34 suggests lower volatility compared to the broader market. Recent trading volume stands at 2,945 shares, which is 0.86 times the 20-day average volume of 3,425 shares.
Insider Activity
No recent insider activity has been reported for Aptose Biosciences, suggesting that there have been no notable transactions by company executives in the recent past.
Price Action Summary
Aptose Biosciences Inc closed at C$2.40, reflecting no change over the past day. With a monthly gain of 12.15%, the stock shows some resilience as the company navigates its recent acquisition and ongoing clinical trials.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
